Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.54 |
| ▸ | EIF4H | Q15056 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513908 | 0.88 | PTPN1 (0.56) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4511393 | 0.83 | MEN1 (0.62) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29653970 | 0.83 | MEN1 (0.62) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11233622 | 0.80 | MEN1 (0.62) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27599336 | 0.79 | MEN1 (0.76) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8620986 | 0.78 | MEN1 (0.73) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3314902 | 0.77 | MEN1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29728200 | 0.77 | MEN1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL30645379 | 0.77 | MEN1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27599072 | 0.77 | MEN1 (0.71) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | MEN1 732/4885KMT2A 3194/4885ALDH1A1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.